Arguments favoring early treatment of Parkinson's disease with L-Dopa;Arguments en faveur du traitement initial de la maladie de Parkinson par la L-Dopa

Revue Neurologique

Volumn 155, Issue 1, 1999, Pages 27-45

  Broussolle, E ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; NOTE; PARKINSON DISEASE; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FREE RADICALS; HUMANS; LEVODOPA; LIFE EXPECTANCY; PARKINSON DISEASE; TIME FACTORS;

EID: 0033066404     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (79)

1. AGID Y. (1991). Parkinson's disease: pathophysiology. Lancet 337: 1321-1324.
2. BARBEAU A. (1976). Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 33: 333-338.
3. BASMA A.N., MORRIS E.J., NICKLAS W.J., GELLER H.M. (1995). L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64 : 825-832.
4. BATTISTIN L., MENEGHETTI G., RIGOTTI S, SAIA A. (1978). Long-term treatment of Parkinson's disease with L-Dopa and decarboxylase inhibitor : therapeutic results and side effect. Acta Neurol Scand 57: 186-192.
5. BEN-SHLOMO Y., MARMOT M.G. (1994). Survival and cause of death in Parkinson's disease : possible clues to aetiology. New Trends Clin Pharmacol 8 : 143.
6. BIRKMAYER W. (1976). Medical treatment of Parkinson's disease -general view, past and present, In Birkmayer W., Hornykiewicz O., (eds.), Advances in Parkinsonism, 407-423, Roche Editions, Basel.
7. BLIN J., BONNET A.M., AGID Y. (1988). Does levodopa aggravate Parkinson's disease ? Neurology 38 : 1410-1416.
8. BLOCK G., LISS C., REINES S., IRR J., NIBBELINK D.C. (1997). The FIRST Study Group, Comparison of immediate release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. Eur Neurol 37 : 23-27.
9. BONNET A.M., LORIA Y., SAINT-HILAIRE M.H., LHERMITTE F., AGID Y. (1987). Does long-term aggravation of Parkinson's disease result from non-dopaminergic lesions ? Neurology 37 : 1539-1542.
10. BROUSSOLLE E. (1997). Traitement d'une maladie de Parkinson débutante. Médecine Thérapeutique 3 : 202-206.
11. CARACENI T., SCIGLIANO G., MUSICCO M. (1991). The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa : role of early treatment and disease progression. Neurology 41 : 380-384.
12. CASTAIGNE P., RONDOT P., RIBADEAU-DUMAS J.L., CARDON P. (1976). Long-term treatment of Parkinson's disease with l-dopa alone and in combination with a decarboxylase inhibitor. In Birkmayer W., Hornykiewicz O., (eds.), Advances in Parkinsonism, 462-468, Roche Editions, Basel.
13. CEDARBAUM J.M., GANDY S.E., MCDOWELL F.H. (1991). Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 41 : 622-629.
14. CLARKE C.E. (1993). Mortality from Parkinson's disease in England and Wales 1921-1989, J Neurol Neurosurg Psychiatry 56 : 690-693.
15. CLARKE C.E. (1995). Does levodopa therapy delay death in Parkinson's disease ? A review of the evidence, Mov Disord 10 : 250-256.
16. COTZIAS G.C., VAN WOERT M.H., SCHIFFER L.M. (1967). Aromatic amino acids and modification of parkinsonism. N Engl J Med 276 : 374-379.
17. CURTIS L., LEES A., STERN G.M., MARMOT M.G. (1984). Effect of L-Dopa on course of Parkinson's disease. Lancet 1 : 211-212.
18. DE JONG G.J., MEERWALDT J.D., SCHMITZ P.I.M. (1987). Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 22 : 4-7.
19. DEXTER D., CARTER C., WELLS F.R., JAVOY-AGID F., AGID Y., LEES A.J., JENNER P., MARSDEN C.D. (1989). Basal lipid peroxydation in substantia nigra is increased in Parkinson's disease. J Neurochem 52 : 381-389.
20. DEXTER D.T., CARAYON A., JAVOY-AGID F., AGID Y., WELLS F.R., DANIEL S.E., LEES A.J., JENNER P., MARSDEN C.D. (1991). Alterations in the levels of iron, ferritin, and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 : 1953-1975.
21. DIAMOND S.G., MARKHAM C.H. (1976). Long-term experience with levodopa : efficacy, progression, and mortality, In Birkmayer W., Hornykiewicz O., (eds.), Advances in Parkinsonism, 444-455, Roche Editions, Basel.
22. DIAMOND S.G., MARKHAM C.H. (1990), Longitudinal study of effects of early levodopa treatment on disability and mortality in Parkinson's disease. In Streifler M.B., Korczyn A.D., Melamed E., Youdim M.B.H. (eds.) Advances in Neurology Vol 53, 399-403, Parkinson's disease : Anatomy, Pathology and Therapy, Raven Press, New York.
23. DUPONT E., ANDERSEN A., BOAS J., et al. (1996). Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93: 14-20.
24. DZIEWCZAPOLSKI G., MURER G., AGID Y., GERSHANIK O., RAISMAN-VOZARI R. (1997). Absence of neurotoxicity of chronic l-dopa treatment in 6-hydroxydopamine-lesioned rats. Neuroreport 8 : 975-979.
25. EBMEIER K., CALDER S.A., CRAWFORD J.R., STEWART L., BESSON J.A.O., MUTCH W.J. (1990). Parkinson's disease in Aberdeen : survival after 3.5 years. Acta Neurol Scand 81 : 294-299.
26. FABBRINI G., JUNCOS J., MOURADIAN M.M., SERRATI C., CHASE T.N. (1987). Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 21 : 370-376.
27. FAHN S. (1992). Adverse effects of levodopa, In Olanow C.W., Lieberman A.N., (eds.), The Scientific Basis for the Treatment of Parkinson's Disease, 89-112, Parthenon Publishing Group, Camforth, England.
28. FAHN S. (1996). Controversies in the therapy of Parkinson's disease, In Battistin L., Scarlato G., Caraceni T., Ruggieri S. (eds.), Advances in Neurology Vol. 6, 477-486, Lippincott-Raven Publishers, Philadelphia.
29. FAHN S., BARRETT R.E. (1979). Increase of Parkinsonian symptoms as a manifestation of levodopa toxicity, In Poirier L.J., Sourkes T.L., Bedard P.J. (eds.), Advances in Neurology, Vol. 24, 451-460, Raven Press, New York.
30. FAHN S., BRESSMAN S.B. (1984). Should levodopa therapy for parkinsonism be started early or late ? Evidence against early treatment. Can J Neurol Sci 11 : 200-206.
31. FAHN S, COHEN G. (1992). The oxidant stress hypothesis in Parkinson's disease : evidence supporting it. Ann Neurol 32 : 804-812.
32. GERVAS J.J., MURADAS V., BAZAN L., et al. (1983). Effects of 3-O-methyl-dopa on monoamine metabolism in rat brain. Neurology 33 : 278-282.
33. GIBB W.R.G. LEES A.J. (1988). The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 : 745-752.
34. GUILLARD A., CHASTABG C., FENELON G. (1986). Étude à long terme de 416 cas de maladie de Parkinson. Facteurs de pronostic et implications thérapeutiques. Rev Neurol (Paris) 142 : 207-214.
35. HALLIWELL B., GUTTERIDGE J.M.C. (1985). Oxygen radicals and the nervous system. Trends Neurosci 8 : 22-26.
36. HEFTI F., MELAMED E., BHAWAN J., WURTMAN R.J. (1981). Long-term administration of L-Dopa does not damage dopaminergic neurons in the mouse. Neurology 31 : 1194-1195.
37. HIRSCH E.C., BRANDEL J.P., GALLE P., JAVOY-AGID F., AGID Y. (1991). Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease : an X-ray microanalysis. J Neurochem 56 : 446-451.
38. HOEHN M.M. (1986). Parkinson's disease : progression and mortality. In Yahr M.D., Bergmann K.J. (eds.), Advances in Neurology Vol. 45, 457-461, Raven Press, New York.
39. HOEHN M.M., YAHR M.D. (1967). Parkinsonism : onset, progression, and mortality. Neurology 17 : 427-442.
40. HORNYKIEWICZ O., KISH S.J. (1986). Biochemical pathophysiology of Parkinson's disease. In Yahr M.D., Bergmann K.J. (eds.), Advances in Neurology Vol. 45, 19-34, Raven Press, New York.
41. HUGUES A.J., DANIEL S.E., BLANKSON S., LEES A.J. (1993). A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50 : 140-148.
42. JENNER P., SCHAPIRA A.H.V., MARSDEN C.D. (1992). New insights into the cause of Parkinson's disease. Neurology 42 : 2241-2250.
43. KOLLER W.C. (1992). Initiating treatment of Parkinson's disease. Neurology 42 (Suppl.) : 33-38.
44. LEES A.J. (1986). L-Dopa treatment in Parkinson's disease. Quarterly J Med New Series 59 : 535-547.
45. LESSER R.P., FAHN S., SINDER S.R., COTE L.J., ISGREEN W.P., BARRETT R.E. (1979). Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa-therapy. Neurology 29 : 1253-1260.
46. MARKHAM C.H., DIAMONDS S.G., TRECIOKAS L.J. (1974). Carbidopa in Parkinson's disease and in nausea and vomiting of levodopa. Arch Neurol 31 : 128-133.
47. MARKHAM C.H., DIAMOND S.G. (1981). Evidence to support early levodopa therapy in Parkinson's disease. Neurology 31 : 125-131.
48. MARSDEN C.D. (1994). Parkinson's disease. J Neurol Neurosurg Psychiatry 57 : 672-681.
49. MARSDEN C.D., PARKES J.D. (1977). Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 : 345-349.
50. MARSDEN C.D., PARKES J.D., QUINN N. (1982). Fluctuations in disability in Parkinson's disease : clinical aspects. In Marsden C.D., Fahn S. (eds.), Movement Disorders, 96-122, Butterworth Scientific, London.
51. MARTILLA R.J., RINNE U.K., SIIRTOLA T., SONNINEN V. (1977). Mortality of patients with Parkinson's disease treated with levodopa. J Neurol 216 : 147-153.
52. MENA M.A., PARDO B., CASAREJOS M.J., FAHN S., GARCIA DE YEBENES J. (1992). Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 7 : 23-31.
53. MERELLO M., LEES A.J., WEBSTER R., BOVINGDON M., GORDIN A. (1994). Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57 : 186-189.
54. MONTGOMERY E.B. (1992). Pharmacokinetics and pharmacodynamics of levodopa. Neurology 42 (Suppl. 1) : 17-22.
55. MOURADIAN N.M., JUNKOS J.L., FABBRINI G. et al. (1988). Motor fluctuations in Parkinson's disease : central pathophysiological mechanisms, Part II. Ann Neurol 24 : 372-378.
56. MUGUET D., BROUSSOLLE E., CHAZOT G. (1995). Apomorphine in patients with Parkinson's disease. Biomed & Pharmacother 49 : 197-209.
57. MYTILINEOU C., HAN S.-K., COHEN G. (1993). Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 61 : 1470-1478.
58. NUTT J.G. (1990). Levodopa-induced dyskinesia : review, observations, and speculations. Neurology 40 : 340-345.
59. OLANOW C.W. (1992). Early therapy for Parkinson's disease. Eur Neurol 32 (Suppl. 1) : 30-35.
60. PARDO B., MENA M.A., CASAJEROS M.J., PAINO C.L., DE YEBENES J.G. (1995). Toxic effets of L-DOPA on mesencephalic cell cultures : protection with antioxydants. Brain Res 682 : 133-143.
61. PARKINSON STUDY GROUP. (1993). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 : 176-183.
62. PERL D.P., GOOD P.F., OLANOW C.W. (1992). Iron(Fe) and aluminium (Al) accumulate in the neuromelanin granules of pigmented neurones in the substantia nigra pars compacta (SNc) of idiopathic Parkinson's disease. J Neuropathol Exp Neurol 51 : 327.
63. PERRY T.L., GODIN D.V., HANSEN S. (1982). Parkinson's disease : a disorder due to nigral gluthatione deficiency ? Neurosci Lett 33 : 305-310.
64. PERRY T.L., WEE YONG V., ITO M. (1984). Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-Dopa and carbidopa chronically. J Neurochem 43 : 990-993.
65. PINDER R.M., BROGDEN R.N., SAWYER P.R., SPEIGHT T.M., AVERY G.S. (1976). Levodopa and decarboxylase inhibitors : A review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 11 : 329-377.
66. POEWE W.H., LEES A.J., STERN G.M. (1986). Low-dose L-Dopa therapy in Parkinson's disease : a six-year follow-up study. Neurology 36 : 1528-1530.
67. QUINN N., PARKES D., JANOTA I., MARSDEN C.D. (1986). Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four year period. Mov Disord 1 : 65-68.
68. QUINN N., CRITCHLEY P., MARSDEN C.D. (1987). Young onset Parkinson's disease. Mov Disord 2 : 73-91.
69. RAJPUT A.H., FENTON M.E., BIRDI S., MACAULAY R. (1997). Is levodopa toxic to human substantia nigra ? Mov Disord 12 : 634-638.
70. RINNE U.K. (1990). Controlled-release levodopa superior to standard levodopa in the treatment of early Parkinson's disease. Mov Disord 5 (suppl 1) : 52.
71. ROBERTS J.W., CORA-LOCATELLI G., BRAVI D., AMANTEA M.A., MOURADIAN M.M., CHASE T.N. (1994). Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 44 : 2685-2688.
72. SANDLER M., JOHNSON R.D., RUTHVEN C.R.J., et al. (1974). Transamination is a major pathway of L-Dopa metabolism following peropheral decarboxylase inhibition, Nature 247 : 364-366.
73. SCHAPIRA A.H.V. (1994). Evidence for mitochondrial dysfunction in Parkinson's disease : a critical appraisal. Mov Disord 9 : 125-138.
74. SCIGLIANO G., MUSICCO M., SOLIVERI P., PICCOLO I., GIROTTI F., GIOVANNINI P., CARACENI T. (1990). Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 40 : 265-269.
75. SENGSTOCK G.J., OLANOW C.W., DUNIN A.J. et al. (1992). Iron induces degeneration of substantia nigra neurons. Brain Res Bull 28 : 645-649.
76. TOLOSA E. (1992). Therapeutic aspects of Parkinson's disease : current strategies in L-Dopa administration. In Agid Y. (editor), Current Trends in the Treatment of Parkinson's disease, 49-55, John Libbey & Company Ltd, London.
77. VERHAGEN METMAN L., LOCATELLI E.R., BRAVI D., MOURADIAN M.M., CHASE T.N. (1997). Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 48 : 369-372.
78. YAHR M.D. (1976). Evaluation of long-term therapy in Parkinson's disease : mortality and therapeutic efficacy. In Birkmayer W., Hornykiewicz O., (eds.), Advances in Parkinsonism, 435-443, Roche Editions, Basel.
79. YOUDIM M.B.H., BENSHACHAR D., RIEDERER P. (1989). Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin-induced neurodegeneration ? Acta Neurol Scand 126 : 47-54.